Repository logo
 

Myc instructs and maintains pancreatic adenocarcinoma phenotype

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Sodir, Nicole 
Kortlever, Roderik 
Barthet, Valentin JA 
Campos, Tania 

Abstract

The signature features of pancreatic ductal adenocarcinoma (PDAC) are its fibroinflammatory stroma, poor immune activity and dismal prognosis. We show that acute activation of Myc in indolent PanIN epithelial cells in vivo is, alone, sufficient to trigger immediate release of instructive signals that together coordinate changes in multiple stromal and immune cell types and trigger transition to pancreatic adenocarcinomas that share all the characteristic stromal features of their spontaneous human counterpart. We also demonstrate that this Myc-driven PDAC switch is completely and immediately reversible: Myc deactivation/inhibition triggers meticulous disassembly of advanced PDAC tumor and stroma and concomitant death of tumor cells. Hence, both the formation and deconstruction of the complex PDAC phenotype are continuously dependent on a single, reversible Myc switch.

Description

Keywords

32 Biomedical and Clinical Sciences, 3204 Immunology, Digestive Diseases, Cancer, Genetics, Rare Diseases, Pancreatic Cancer, Animals, Carcinoma, Pancreatic Ductal, Genes, myc, Humans, Mice, Pancreatic Neoplasms, Phenotype, Prognosis, Proto-Oncogene Proteins c-myc, Proto-Oncogene Proteins p21(ras)

Journal Title

Cancer Discovery

Conference Name

Journal ISSN

2159-8274
2159-8290

Volume Title

Publisher

American Association for Cancer Research Inc.

Rights

All rights reserved
Sponsorship
European Research Council (294851)
Cancer Research UK (19013)
Cancer Research UK (22585)
European Commission (302265)
Cancer Research UK (via University of Glasgow) (301442)
The study was supported by program grants to G.I.E. (Cancer Research UK C4750/A12077 and C4750/A19013A, European Research Council (294851), and a Stand Up To Cancer-Cancer Research UKLustgarten Foundation Pancreatic Cancer Dream Team Research Grant (Grant Number: SU2C-AACR-DT20-16). Stand Up To Cancer is a division of the Entertainment Industry Foundation and the research grant is administered by the American Association for Cancer Research, the Scientific Partner of SU2C.